The Amsterdam universities strongly encourage research collaborations. Deploying the power of research to ensure benefits for society in whatever form is always a collaborative effort.
In research collaborations with Amsterdam researchers, by pooling expertise and facilities, you can explore new grounds, generate new insight and strengthen your innovative power. IXA’s business developers are more than happy to help you find relevant researchers and facilitate fruitful interactions. Whether you’re interested in sponsoring a research project, setting up a strategic alliance, or accessing laboratory facilities, we can help you launch a successful collaboration.
We are aware that fruitful collaboration requires an environment where open discussions and exchange of information is safeguarded by a framework that respects the interests of all parties involved. It goes without saying that proper arrangements have to be made regarding ownership of research results, as well as rights to exploitation and publication. IXA has extensive experience in handling all legal and financial aspects concerning research collaborations. Our approach is to enable partnerships that offer truly added value for all participants.
Optics11 and Optics11 Life have secured funding from Rabobank. The funding will be used to strongly accelerate growth across global markets, to further build the team for the future and to strategically expand the high-tech product portfolios of both business units. “This is the right moment to pick up the pace. Rabobank’s funding helps us […]News
Is it possible to create a cup of coffee that’s healthy and tasty? At the entrepreneurship laboratory Demonstrator Lab at the Vrije Universiteit, Florian Fermin (27) and Stefan Wateler (26) developed Cuppelement, a Fairtrade biodegradable coffee capsule with added superfoods and vitamins. During the Dutch TV program Dragons Den, the entrepreneurs successfully persuaded the dragons […]News
Azafaros B.V. announced today that the first cohort of healthy subjects has been dosed in a two-part Phase 1 clinical study with clinical candidate AZ-3102, a first-in-class small molecule compound being developed for the treatment of rare neurogenetic disorders. This double-blind, placebo-controlled, Phase 1 study is evaluating the safety and tolerability of ascending single- (SAD) […]News